Chris Spivey

One can only learn the secrets of "fight club" by attending its meetings.

More than anything else MonkeyPox and COVID-19 have shown that we are interdependent, no matter what continent you call home.

Promising applications for targeted delivery may be cresting the horizon.

As we reach further afield in the molecular universe, we encounter new types of problems to resolve.

Lions and tigers and monkeypox, oh my!

Demand for outsourced services of technical R&D activities is increasing.

FDA is incentivizing drug manufacturers through higher data integrity requirements.

Fresh insight is instrumental in the discussion of novel analytics.

Researchers from the Telomere-to-Telomere Consortium have discovered new properties about junk DNA that could have wide-reaching implications.

3D cell cultures could provide key avenues to unlocking critical information.

Borrowing is good, but invention is best.

The process of reshaping inevitably leads to fresh insights.

Warp speed is amazoning pharma practices and protocols.

We have broken rules, invented new ones, and engineered stronger institutions and supply chains that will serve us better going forward.

Global supply chain experts examine implications of the DSCSA as well as topical considerations around the EU's FMD in this serialization video series ft. manufacturing, packaging, software, and regulatory experts.

Global supply chain experts examine implications of the DSCSA as well as topical considerations around the EU's FMD in this serialization video series ft. manufacturing, packaging, software, and regulatory experts.

Global supply chain experts examine implications of the DSCSA as well as topical considerations around the EU's FMD in this serialization video series ft. manufacturing, packaging, software, and regulatory experts.

Global supply chain experts examine implications of the DSCSA as well as topical considerations around the EU's FMD in this serialization video series ft. manufacturing, packaging, software, and regulatory experts.

Part 2—Industry experts from MilliporeSigma, Lonza, Astrea Bioseparations, and Sartorius provide insight and examples about solving critical challenges in both analytics and process development for emerging therapies.

Part 1—Industry experts from MilliporeSigma, Lonza, Astrea Bioseparations, and Sartorius discuss key issues affecting the development of emerging biotherapies.

Change of roster does not change the goal line. We are all patients first.